Spark Biopharma
Clinical trials sponsored by Spark Biopharma, explained in plain language.
-
New drug aims to slow lung scarring in IPF patients
Disease control Recruiting nowThis study tests an experimental drug called SB17170 in 30 adults aged 40 and older with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing problems. Participants will receive either the drug or a placebo for 12 weeks. The main goal is to see i…
Phase: PHASE2 • Sponsor: SPARK Biopharma • Aim: Disease control
Last updated May 26, 2026 09:32 UTC
-
New hope for Hard-to-Treat cancers: early trial begins
Disease control Recruiting nowThis early-phase study tests a new drug, SB17170, in about 50 adults with advanced solid tumors that no longer respond to standard treatments. The main goal is to find a safe dose and check for side effects. Researchers will also measure how the drug moves through the body and lo…
Phase: PHASE1 • Sponsor: SPARK Biopharma • Aim: Disease control
Last updated May 26, 2026 09:30 UTC